Other substances

Prazosin

alpha-1 adrenergic receptor antagonist

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
1
 Clinical trials

 

Supporting references

Link Tested on Impact factor Notes Publication date
Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome
Cytokine storm Preprint 		Patients Apr/18/2020

AI-suggested references

Link Publication date
The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19.
Mar/31/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04365257 Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) Recruiting Phase 2 May/13/2020 Mar/30/2022
  • Alternative id - IRB00246659|COV2001
  • Interventions - Drug: Prazosin|Other: Standard of care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Johns Hopkins Hospital, Baltimore, Maryland, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 220
  • Age - 45 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - Death|Hospitalized, requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO|Hospitalized, requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2)|Cumulative incidence of grade 3 and 4 adverse events|Number of participants with serious adverse events|Incidence of symptomatic hypotension or hypotension requiring cessation of prazosin|Number of participants with laboratory abnormalities in peripheral blood|Duration of laboratory abnormalities in peripheral blood|Number of participants with laboratory abnormalities in plasma|Duration of laboratory abnormalities in plasma
Export (.csv)